Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Takeda
The drug being tested in this survey is called Leuprorelin for Injection Kit 22.5 mg. Leuprorelin is being tested to treat people who have premenopausal breast cancer.
This survey will look at the safety in patients with premenopausal breast cancer receiving the drug in the routine clinical setting.
The survey will enroll approximately 300 patients.
\- Leuprorelin
This multi-center survey will be conducted in Japan.
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
\- Participants with premenopausal breast cancer will be included.
You may not be if
Participants with a history of hypersensitivity to any ingredients of Leuplin PRO, synthesized LH-RH, or LH-RH analogues
Pregnant or potentially pregnant participants and breastfeeding participants
Clareo Health | Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
